Skip to main content
Update Location

My Location

Update your location to show providers, locations, and services closest to you.

Enter a zip code
Or
Select a campus/region

Michael J Haller, MD : Research

Pediatric Endocrinologist (Child Hormone Specialist)

Photo of Michael J Haller

Research at a glance

Top areas of exploration

  • Diabetes Mellitus, Type 1 , 60 publications
  • Insulin , 15 publications
  • Blood Glucose , 13 publications
  • Glycated Hemoglobin , 12 publications

Research activity

128 publications

2,991 citations

Why is this important?

Focus

Dr. Haller's research focuses on predicting, preventing, and ultimately reversing type 1 diabetes through his participation in numerous clinical trials utilizing immunotherapies. Dr. Haller serves as the Principal Investigator for the University of Florida TrialNet Clinical Center, Chair of the TEDDY Clinical Implementation Committee, and PI of the UF/Stanford ECHO Collaborative. Dr. Haller also leads and participates in technology studies seeking to improve the lives of people living with diabetes through the use of pumps, continuous glucose monitors, and systems that automate insulin delivery.

Active clinical trials

TN-31 JAKPOT T1D

A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.

Investigators
Laura Jacobsen, Michael J Haller
Status
Accepting Candidates
Ages
12 Years - 35 Years
Sexes
All
Protocol TN-25

The study is a two-arm, multicenter, double-blinded clinical trial testing sequential therapy with rituximab-pvvr followed by abatacept versus rituximab-pvvr alone in new onset T1D. The primary objective is to test whether the C-peptide response to…

Investigators
Laura Jacobsen, Michael J Haller
Status
Accepting Candidates
Ages
8 Years - 45 Years
Sexes
All
Protocol TN-28

A multi-center, placebo-controlled, double blind, 2:1 randomized control clinical trial testing low-dose ATG vs. placebo in subjects with a 2 year 50% risk of progression to stage 3 T1D.

Investigator
Michael J Haller
Status
Accepting Candidates
Ages
6 Years - 34 Years
Sexes
All

My publications

128 publications

2023

CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study

Diabetes Care

PubMed Publisher's site

2023

Disease progression joint model predicts time to type 1 diabetes onset: Optimizing future type 1 diabetes prevention studies.

CPT: pharmacometrics & systems pharmacology

PubMed Publisher's site